Social Survey Research Information Co., Ltd.
- Announcement about survey for physicians' survey database "PatientsMap" US version to be conducted (24/08/08)
- Rare Disease Day 2024
--- Focusing on treatment gaps in rare diseases --- (24/02/29) - Analysis of the prevalence of digital therapeutics (DTx) among physicians and the expectations they have
--PatientsMap 2023 Japan version— (24/01/30) - PatientsMap 2023 Japan version is now available (23/10/25)
- Analysis of the potential for administering new drugs in terms of the number of patients
- from PatientsMap2022JP version - (23/09/07) - Analysis of the potential for administering new drugs in terms of the number of patients
- from PatientsMap2022JP version - (23/07/21) - PatientsMap 2022 US version now available (23/02/02)
- PatientsMap 2022 Japan version now available (22/11/11)
- Analysis by scale of hospitals and cities by the top 10 companies in China in terms of sales rep activities (6 foreign-funded and 4 domestic-funded). (22/08/25)
- PatientsMap 2022 Japan Survey Begins. (22/06/28)
- PatientsMap analysis of Chinese physicians’ needs for new drugs (22/06/09)
- Launch of PatientsMap China 2022 (22/04/22)
- Analysis of trends in the needs for new drugs with PatientsMap data (22/02/28)
- Increase in symptoms of depression and anxiety worldwide due to COVID-19 (21/03/05)
- Final Results of Cyberattack Incident Investigation (20/12/14)
- PatientsMap database is now available in English. Try out the demo version! (20/09/02)
- Launch of PatientsMap 2017 JP (17/12/07)
- Market Potential with new product needs in USA (17/07/24)
- China’s COPD market research report – now available (16/09/06)
- CI Insight Report "Research of China’s COPD Market" (16/05/06)
- Medical conditions with new product needs: A comparison of US vs. Japan through a large-scale physician survey (PatientsMap) Click here to see the full press release (PDF) (16/02/10)
- SSRI CHINA completes its investment in HIMA, a Shanghai-based pharmaceutical market research company. Click here to see the full press research (PDF) (15/08/21)
- We welcome HIMA as an SSRI group company (15/08/21)
- Top unmet medical need: Obesity (US) vs. Dementia (Japan) (15/08/04)